| # | Drug | Count |
|---|---|---|
| 0 | ECULIZUMAB | 58 |
| 1 | RAVULIZUMAB | 19 |
| 2 | MYCOPHENOLATE MOFETIL | 16 |
| 3 | MYCOPHENOLATE MOFETIL HYDROCHLORIDE | 16 |
| 4 | AZATHIOPRINE | 15 |
| 5 | RITUXIMAB | 15 |
| 6 | BELIMUMAB | 12 |
| 7 | FOLIC ACID | 11 |
| 8 | METHOTREXATE SODIUM | 11 |
| 9 | ETANERCEPT | 10 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | LINCOMYCIN HYDROCHLORIDE | 1 | 0.0034 |
| 1 | PENICILLIN V POTASSIUM | 7 | 0.0027 |
| 2 | NAFCILLIN SODIUM | 1 | 0.0011 |
| 3 | ECULIZUMAB | 58 | 0.0011 |
| 4 | HUMAN IMMUNOGLOBULIN G | 9 | 0.0004 |
| 5 | PENICILLIN G | 1 | 0.0004 |
| 6 | CALCIFEDIOL | 1 | 0.0004 |
| 7 | DEFLAZACORT | 1 | 0.0004 |
| 8 | BELIMUMAB | 12 | 0.0004 |
| 9 | COAGULATION FACTOR VIIA (RECOMBINANT) | 1 | 0.0004 |
| # | Drug class | Count |
|---|---|---|
| 0 | Complement Inhibitor [EPC] | 77 |
| 1 | Corticosteroid [EPC] | 18 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 16 |
| 3 | Purine Antimetabolite [EPC] | 16 |
| 4 | Tumor Necrosis Factor Blocker [EPC] | 16 |
| 5 | B Lymphocyte Stimulator-specific Inhibitor [EPC] | 12 |
| 6 | Vitamin C [EPC] | 12 |
| 7 | Vitamin B12 [EPC] | 11 |
| 8 | Vitamin D [EPC] | 11 |
| 9 | Human Immunoglobulin G [EPC] | 9 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Complement Inhibitor [EPC] | 77 | 0.0014 |
| 1 | Human Immunoglobulin G [EPC] | 9 | 0.0004 |
| 2 | B Lymphocyte Stimulator-specific Inhibitor [EPC] | 12 | 0.0004 |
| 3 | Sulfonamide Antibacterial [EPC] | 1 | 0.0003 |
| 4 | Purine Antimetabolite [EPC] | 16 | 0.0002 |
| 5 | Dopamine-2 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 6 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 3 | 0.0001 |
| 7 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 8 | Interleukin-17A Antagonist [EPC] | 4 | 0.0001 |
| 9 | Provitamin D2 Compound [EPC] | 3 | 0.0001 |